EcoDrugPlus

Protein Kinase D3

Ensembl ID : ENSPPRG00000003387
Gene Symbol: PRKD3
3 Cross references
270 Possible Orthologues:

Protein Kinase Camp-Activated Catalytic Subunit Alpha

Ensembl ID : ENSPPRG00000023771
Gene Symbol: PRKACA
4 Cross references
283 Possible Orthologues:

Protein Kinase Camp-Activated Catalytic Subunit Beta

Ensembl ID : ENSPPRG00000015792
Gene Symbol: PRKACB
4 Cross references
297 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSPPRG00000013209
Gene Symbol: PRKDC
3 Cross references
184 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSPPRG00000014654
Gene Symbol: PPP3CA
4 Cross references
230 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSPPRG00000003723
Gene Symbol: PTK2
3 Cross references
323 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSPPRG00000007277
Gene Symbol: PTK2B
4 Cross references
269 Possible Orthologues:

Protein Tyrosine Kinase 6

Ensembl ID : ENSPPRG00000009136
Gene Symbol: PTK6
4 Cross references
170 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSPPRG00000003977
Gene Symbol: PTPN11
4 Cross references
251 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSPPRG00000001785
Gene Symbol: PTPRB
4 Cross references
264 Possible Orthologues:

Purine Nucleoside Phosphorylase

Ensembl ID : ENSPPRG00000011231
Gene Symbol: PNP
4 Cross references
429 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSPPRG00000014554
Gene Symbol: P2RX3
4 Cross references
270 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).